The T-Cell Engager field is at a turning point, with recent approvals, groundbreaking deals, and surging investment shaping the next generation of cancer immunotherapies. Biotech and pharma leaders are advancing first-in-class, safe, and highly efficacious therapies, pushing toward the next major regulatory breakthrough.

Join C-level executives, VPs, and directors from across the industry as they tackle key challenges, including enhancing therapeutic potency, mitigating on-target, off-tumor toxicity, optimizing drug constructs, and improving durability of response. Companies are actively seeking partnerships with CROs, CDMOs, CRS assay providers, and antibody discovery experts to accelerate discovery, optimize clinical translation, and de-risk first-in-human studies.

With T-cell engagers redefining immunotherapy, this summit is your platform to shape the competitive landscape, drive innovation, and forge lasting partnerships.